IRTCNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
iRhythm Holdings, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$109.60+0.94 (+0.87%)
Close on Oct 19, 2026
- Market cap
- $3.61B
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2013 to 2025
Gross margin
70.6%−2.9 pts over 5 years
Operating margin
-7.7%+8.8 pts over 5 years
Net margin
-6.0%+10.6 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +26.2% | +22.1% | +23.0% | +35.4% | |
| Gross profit | +29.4% | +23.2% | +22.0% | +37.7% |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | 487.1% | -18.4% | -36.6% | |
| Return on assets | -23.7% | -10.7% | -4.6% | |
| Current ratio | 8.98 | 5.75 | 4.63 | |
| Debt to equity | 0.35 | 0.10 | – | |
| Net debt to EBITDA | 1.30× | 1.51× | – | |
| Interest coverage | -4.8× | -28.8× | -4.4× | |
| Inventory turnover | 16.5× | 15.0× | 12.3× | |
| Capex to revenue | 4.3% | 5.1% | 6.2% | |
| Diluted shares | 5M | 28M | 32M |
Where the cash went
Fiscal 2021 to 2025, five years combined
iRhythm generated $195.12M from operations and spent $203.61M on capital expenditure, dividends and share buybacks. 88% of that went back into the business.
Generated
$195.12M
Used
$203.61M
Capital expenditure$178.61M88%Dividends$00%Share buybacks$25.00M12%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-6.0%
×Asset turnover0.77×
×Equity multiplier8.01×
=Return on equity, FY2025-36.6%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | -6.0% | 0.77× | 8.01× | -36.6% |
| FY2024 | -19.1% | 0.87× | 4.53× | -75.3% |
| FY2023 | -25.0% | 1.12× | 1.96× | -54.9% |
| FY2022 | -28.3% | 0.90× | 1.75× | -44.7% |
| FY2021 | -31.4% | 0.66× | 1.57× | -32.6% |
| FY2020 | -16.5% | 0.65× | 1.71× | -18.4% |
| FY2019 | -25.4% | 1.01× | 2.26× | -58.2% |
| FY2018 | -34.2% | 1.17× | 1.91× | -76.6% |
| FY2017 | -30.0% | 0.73× | 1.58× | -34.5% |
| FY2016 | -32.6% | 0.73× | -20.51× | 487.1% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
4of 8 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$44.55M
- Cash generatingOperating cash flow above zero$80.86M
- Return on assets improvedROA up on the prior year-26.2% → -4.8%
- Earnings backed by cashOperating cash flow above net income$80.86M vs -$44.55M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose5.82 → 4.63
- No dilutionShare count did not rise31M → 32M
- Gross margin improvedGross margin up on the prior year68.86% → 70.57%
- More efficientAsset turnover rose1.37 → 0.80